Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia
Study Details
Study Description
Brief Summary
This study aims to evaluate topical application of Cocaine HCl 4% and 10% on safety and efficacy in local (topical) anesthesia for diagnostic procedures and surgeries on or through accessible mucous membranes of the nasal cavities.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Randomized, prospective, multisite, double-blind, placebo-controlled, parallel-group study of a Placebo Topical Solution versus Cocaine HCl 4% or 10% Topical Solution as an anesthetic prior to a diagnostic procedure or surgery.
In the Safety and Efficacy first phase, subjects will be randomized in a 1:1:1 fashion to one of the three treatment groups (placebo, Cocaine HCl 4% or 10% topical solution) pre-procedure and given one application of up to 4 mL from one bottle of the assigned test product. After pre-procedure Von Frey filament testing, the blind will be broken, but only relative to placebo versus cocaine, not relative to the strength of the cocaine. The placebo subjects will then exit participation in the efficacy portion of the trial, and be followed for safety for 7 days. Treatment group subjects who do not feel pain after Von Frey testing will receive their surgery or diagnostic procedure and also be followed for safety for 7 days.
In the Safety second phase, subjects will be randomized in a 1:1 fashion to one of the two treatment groups (Cocaine HCl 4% or 10% topical solution) pre-procedure and given one application of up to one 4 mL of the assigned test product. After pre-procedure Von Frey filament testing reveals a pain score of 0, subjects will receive their surgery or diagnostic procedure, and then all subjects will be followed for safety for 7 days.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Group 1, Placebo Topical Solution Group 1: Placebo group -Placebo solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . All placebo subjects, regardless of Von Frey filament test results, will undergo Phase 1 recovery (i.e. at least 90 minutes after cotton pledget removal) and associated required study procedures (including the final 12 lead ECG). After a minimum of 24 hours from the time of study drug pledget removal, the subject may continue the procedure, and the treatment reverts to standard anesthetic management (suitable products at the discretion of the investigator). Alternatively, at the investigator's discretion, the diagnostic procedure or surgery may be delayed until study termination. |
Drug: Placebo Topical Solution
Placebo Topical Solution
|
| Active Comparator: Group 2, Cocaine HCl 4% Topical Solution Group 2: Cocaine HCI 4% Group - Cocaine HCl 4% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total amount of Cocaine HCl 4% topical solution used will be recorded. |
Drug: Cocaine HCl 4% Topical Solution
Cocaine HCl 4% Topical Solution
|
| Active Comparator: Group 3, Cocaine HCl 10% Topical Solution Group 3: Cocaine HCI 10% Group - Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total amount of Cocaine HCl 10% topical solution used will be recorded. |
Drug: Cocaine HCl 10% Topical Solution
Cocaine HCl 10% Topical Solution
|
Outcome Measures
Primary Outcome Measures
- Immediate and Sustained Analgesic Success [Prior to and During a one-day Surgery or Diagnostic Procedure]
The primary endpoint for this trial is analgesic success immediately after application of study drug and sustained throughout the diagnostic procedure or surgery for each nostril that received the study drug application. A subject will be considered a treatment success if they meet the following: Prior to the procedure or surgery, a 0 pain score on the 10 point pain scale (0=no pain, 10=unbearable pain) based on the Von Frey filament challenge after application of the assigned treatment solution (placebo, 4% or 10% Cocaine HCl). During the procedure or surgery, no further analgesic treatment is required (only 4% and 10% Cocaine HCl subjects who receive a procedure or surgery). Otherwise, the subject will be considered a treatment failure. Subjects with missing primary outcome data are marked as treatment failures in all treatment groups.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Provide written informed consent and HIPAA authorization. Residents of California must also review and sign the California Subject Bill of Rights.
-
Male or female ≥18 years of age.
-
Predetermined need from a physician for a diagnostic procedure or surgery of or through the nasal mucous membranes of either one or two nostrils.
-
Ability to feel pain sensation normally in the nasal mucous membranes, as verified via Von Frey 5.18 monofilament testing.
-
Ability to clearly communicate pain and sensation of the nasal mucous membranes.
Exclusion Criteria:
-
Has a known allergy to any ester based anesthetics including cocaine HCl, procaine, tetracaine, chloroprocaine, dibucaine, or benzocaine, and/or any other compounds of the drugs and/or devices that are part of this protocol. (Amide based anesthetic allergies are NOT exclusionary. Amide based anesthetics are: Lidocaine, Mepivicaine, Bupivicaine, Levobupivicaine, Ropivicaine, Etidocaine, Prilocaine, and Articaine).
-
Has a history of abuse of controlled substances, nasal or otherwise, or has damage to the nasal space that in the opinion of the investigator might interfere with the ability of the subject or the investigator to judge anesthesia from the trial drug.
-
Has used any investigational drug(s) within 30 days preceding the randomization.
-
Is pregnant or is a nursing mother
-
Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study, and for women 30 days and men 90 days after the last dose of investigational product in such a manner that the risk of pregnancy and risk to pregnancy is minimized.
-
Is < 18 years of age
-
Suffers from a condition, other than the need for a diagnostic procedure or surgery of or through the nasal mucous membranes which, in the opinion of the Investigator, would compromise the safety of the subject and/or the quality of the data, or the normal wound healing process.
-
Use of any analgesic 2 days prior to screening or has a need to use these drugs during the screening period. This includes NSAID such as ibuprofen, diclofenac, indomethacin, sulindac, tolmetin, ketoprofen, flurbiprofen, naproxen, opioids such as codeine, hydrocodone, hydromorphone, morphine, oxycodone, aspirin, or acetaminophen.
-
Subjects who have experienced a seizure while taking isoniazid (INH), phenothiazines, chlorpromazine, thioridazine, theophylline, or tricyclic antidepressants such as amitriptyline.
-
Has previously received study drug during this study. Subjects who fail screening may rescreen if eligibility requirements are met.
-
Has a history of myocardial infarction, coronary artery disease, congestive heart failure, irregular heart rhythm (as fully defined in sections 9.4, 9.5, and 9.6 of the protocol), or uncontrolled hypertension or is taking (or has recently taken) monoamine oxidase inhibitors. Uncontrolled hypertension is defined as systolic blood pressure greater than or equal to 140 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg
-
Has a known personal or family history of hereditary pseudocholinesterase deficiency. Study participants will be screened by asking about personal or family history of anesthetic reaction, anesthetic death, and previous diagnosis of pseudocholinesterase deficiency in a relative or personally. Subjects identified with pseudocholinesterase deficiency are at risk for delayed recovery with certain anesthetics (e.g. succinylcholine and ester-based anesthetics).
-
Has a known personal or family history of pheochromocytoma. Study participants will be specifically asked if they have been treated for a pheochromocytoma previously or if they have a family member who has been diagnosed with pheochromocytoma (since 10% of these are familial).
-
Has a known personal or family history of an adrenal tumor.
-
Use of amphetamines in the 2 days prior to screening or has a need to use these drugs during the course of the study. All stimulant prescription, and nonprescription products such as catecholamines (norepinephrine or epinephrine), ephedrine, pseudoephedrine and any other amphetamines in the 48 hours prior to screening or has a need to use these drugs during the course of the study. All herbal products are also prohibited within 48 hours prior to screening or if the subject has a need to use these drugs during the course of the study.
-
Has screening 12-lead ECG findings of any abnormalities as listed in sections 7.9.4, 7.9.5, and 7.9.6 of the protocol. Generally, these are current or prior myocardial ischemia or infarction, dysrhythmia, or risk of serious dysrhythmia (such as prolonged QT interval) An exception to this would be from 7.9.5.11 if sinus bradycardia or sinus tachycardia is present, the Investigator must determine whether this finding is clinically relevant and exclusionary.
-
Hemoglobin <8.5 g/dL; a one-time retest will be allowed for Hb 8.3-8.4 g/dL
-
WBC < 3.5 x 103 cells/mcL; a one-time retest will be allowed for WBC 3.3-3.4 x 103 cells/mcL
-
Platelets < 100 x 103 platelets/mcL; a one-time retest will be allowed for platelets 90-99x 103 platelets/mcL
-
Serum Potassium <3.5 or >4.5 mEq/L
-
Serum ALT, AST, and bilirubin not exceeding 2X ULN for the lab's reference values
-
Cardiac enzymes outside of the range of normal
-
Coagulation studies that in the opinion of the investigator would be cause for the subject to be excluded from the study.
-
Positive urine pregnancy test at screening or Day 1
-
Positive urine drug test at screening or Day 1 without prior medically-necessary use of controlled substances (for example, benzodiazepines for anxiety)
-
A one-time retest is permitted for any blood test if the original sample was hemolyzed.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Connecticut Sinus Center, PC | Bridgeport | Connecticut | United States | 06606 |
| 2 | Research Across America | Plano | Texas | United States | 75093 |
Sponsors and Collaborators
- Lannett Company, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Protocol COCA4vs10-001
Study Results
Participant Flow
| Recruitment Details | Subjects were recruited from patients scheduled for an office-based or operating room-based procedure or surgery on or through accessible mucous membranes of the nasal cavities. |
|---|---|
| Pre-assignment Detail | A screening visit was conducted to ensure that each subject met inclusion/exclusion criteria for the study. Subjects who met all eligibility criteria were then enrolled on the drug application and procedure visit, which may have taken place on the same day as the screening visit. |
| Arm/Group Title | Cocaine HCl 4% Topical Solution | Cocaine HCl 10% Topical Solution | Placebo Topical Solution | Not Randomized |
|---|---|---|---|---|
| Arm/Group Description | Subjects randomized to receive Cocaine HCl 4% Topical Solution | Subjects randomized to receive Cocaine HCl 10% Topical Solution | Subjects randomized to receive Placebo Topical Solution | Enrolled subjects who are not randomized to treatment due to early withdrawal from the study |
| Period Title: Safety and Efficacy First Phase | ||||
| STARTED | 39 | 41 | 40 | 3 |
| COMPLETED | 39 | 41 | 40 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 3 |
| Period Title: Safety and Efficacy First Phase | ||||
| STARTED | 18 | 18 | 0 | 0 |
| COMPLETED | 18 | 18 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Cocaine HCl 4% Topical Solution | Cocaine HCl 10% Topical Solution | Placebo Topical Solution | Not Randomized | Total |
|---|---|---|---|---|---|
| Arm/Group Description | Subjects randomized to receive Cocaine HCl 4% Topical Solution | Subjects randomized to receive Cocaine HCl 10% Topical Solution | Subjects randomized to receive Placebo Topical Solution | Enrolled subjects who are not randomized to treatment due to early withdrawal from the study | Total of all reporting groups |
| Overall Participants | 57 | 59 | 40 | 3 | 159 |
| Age (years) [Mean (Standard Deviation) ] | |||||
| Mean (Standard Deviation) [years] |
39.26
(12.55)
|
40.98
(12.45)
|
34.58
(13.82)
|
51.67
(16.17)
|
38.96
(13.14)
|
| Sex: Female, Male (Count of Participants) | |||||
| Female |
30
52.6%
|
37
62.7%
|
23
57.5%
|
1
33.3%
|
91
57.2%
|
| Male |
27
47.4%
|
22
37.3%
|
17
42.5%
|
2
66.7%
|
68
42.8%
|
Outcome Measures
| Title | Immediate and Sustained Analgesic Success |
|---|---|
| Description | The primary endpoint for this trial is analgesic success immediately after application of study drug and sustained throughout the diagnostic procedure or surgery for each nostril that received the study drug application. A subject will be considered a treatment success if they meet the following: Prior to the procedure or surgery, a 0 pain score on the 10 point pain scale (0=no pain, 10=unbearable pain) based on the Von Frey filament challenge after application of the assigned treatment solution (placebo, 4% or 10% Cocaine HCl). During the procedure or surgery, no further analgesic treatment is required (only 4% and 10% Cocaine HCl subjects who receive a procedure or surgery). Otherwise, the subject will be considered a treatment failure. Subjects with missing primary outcome data are marked as treatment failures in all treatment groups. |
| Time Frame | Prior to and During a one-day Surgery or Diagnostic Procedure |
Outcome Measure Data
| Analysis Population Description |
|---|
| The analysis of primary outcome data is based on an intent-to-treat population, which includes all randomized subjects who received study drug and who are enrolled in the safety and efficacy phase of the study. |
| Arm/Group Title | Cocaine HCl 4% Topical Solution | Cocaine HCl 10% Topical Solution | Placebo Topical Solution |
|---|---|---|---|
| Arm/Group Description | Subjects randomized to receive Cocaine HCl 4% Topical Solution | Subjects randomized to receive Cocaine HCl 10% Topical Solution | Subjects randomized to receive Placebo Topical Solution |
| Measure Participants | 39 | 41 | 40 |
| Number (95% Confidence Interval) [proportion of particpants analyzed] |
0.5385
|
0.7561
|
0.3750
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Cocaine HCl 4% Topical Solution, Placebo Topical Solution |
|---|---|---|
| Comments | The null hypothesis is that the proportions of treatment group successes are equal. | |
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.1088 |
| Comments | One-sided p-value | |
| Method | Fisher Exact | |
| Comments | ||
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | Cocaine HCl 10% Topical Solution, Placebo Topical Solution |
|---|---|---|
| Comments | The null hypothesis is that the proportions of treatment group successes are equal. | |
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.0005 |
| Comments | One-sided p-value | |
| Method | Fisher Exact | |
| Comments | ||
Adverse Events
| Time Frame | Adverse events were monitored for each subject from the time informed consent was signed until termination from the study, up through the seven day follow up visit. | |||||
|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | Serious classification based on the FDA regulatory definition of a serious AE. | |||||
| Arm/Group Title | Cocaine HCl 4% Topical Solution | Cocaine HCl 10% Topical Solution | Placebo Topical Solution | |||
| Arm/Group Description | Subjects randomized to receive Cocaine HCl 4% Topical Solution | Subjects randomized to receive Cocaine HCl 10% Topical Solution | Subjects randomized to receive Placebo Topical Solution | |||
All Cause Mortality |
||||||
| Cocaine HCl 4% Topical Solution | Cocaine HCl 10% Topical Solution | Placebo Topical Solution | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | / (NaN) | |||
Serious Adverse Events |
||||||
| Cocaine HCl 4% Topical Solution | Cocaine HCl 10% Topical Solution | Placebo Topical Solution | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Cardiac disorders | ||||||
| Myocardial ischaemia | 0/57 (0%) | 0 | 1/59 (1.7%) | 1 | 0/40 (0%) | 0 |
Other (Not Including Serious) Adverse Events |
||||||
| Cocaine HCl 4% Topical Solution | Cocaine HCl 10% Topical Solution | Placebo Topical Solution | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 53/57 (93%) | 55/59 (93.2%) | 35/40 (87.5%) | |||
| Cardiac disorders | ||||||
| Bradycardia | 2/57 (3.5%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Bundle branch block right | 0/57 (0%) | 0/59 (0%) | 1/40 (2.5%) | |||
| Tachycardia | 1/57 (1.8%) | 2/59 (3.4%) | 1/40 (2.5%) | |||
| Eye disorders | ||||||
| Photopsia | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Vision blurred | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Gastrointestinal disorders | ||||||
| Abdominal pain | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Dry mouth | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Hypoaesthesia oral | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Paraesthesia oral | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Investigations | ||||||
| Blood pressure increased | 1/57 (1.8%) | 0/59 (0%) | 1/40 (2.5%) | |||
| Electrocardiogram abnormal | 0/57 (0%) | 0/59 (0%) | 1/40 (2.5%) | |||
| Heart rate decreased | 3/57 (5.3%) | 8/59 (13.6%) | 5/40 (12.5%) | |||
| Heart rate increased | 16/57 (28.1%) | 14/59 (23.7%) | 7/40 (17.5%) | |||
| Metabolism and nutrition disorders | ||||||
| Tetany | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Musculoskeletal and connective tissue disorders | ||||||
| Exostosis | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Nervous system disorders | ||||||
| Syncope | 0/57 (0%) | 0/59 (0%) | 1/40 (2.5%) | |||
| Psychiatric disorders | ||||||
| Anxiety | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Respiratory, thoracic and mediastinal disorders | ||||||
| Hyperventilation | 2/57 (3.5%) | 1/59 (1.7%) | 2/40 (5%) | |||
| Hypoxia | 0/57 (0%) | 0/59 (0%) | 1/40 (2.5%) | |||
| Intranasal paraesthesia | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Nasal polyps | 1/57 (1.8%) | 0/59 (0%) | 0/40 (0%) | |||
| Nasal septum deviation | 0/57 (0%) | 2/59 (3.4%) | 0/40 (0%) | |||
| Rhinalgia | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Rhinorrhoea | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Tachypnoea | 0/57 (0%) | 0/59 (0%) | 1/40 (2.5%) | |||
| Upper-airway cough syndrome | 0/57 (0%) | 1/59 (1.7%) | 0/40 (0%) | |||
| Vascular disorders | ||||||
| Diastolic hypertension | 4/57 (7%) | 2/59 (3.4%) | 2/40 (5%) | |||
| Hypertension | 47/57 (82.5%) | 52/59 (88.1%) | 28/40 (70%) | |||
| Hypotension | 4/57 (7%) | 1/59 (1.7%) | 3/40 (7.5%) | |||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
Sponsor right of review of publication, right to remove confidential or proprietary information, and all multi-center data publication done before any additional publications.
Results Point of Contact
| Name/Title | Lori Christman, PhD |
|---|---|
| Organization | STATKING Clinical Services |
| Phone | 513-858-2989 ext 317 |
| lori@statkingclinical.com |
- Protocol COCA4vs10-001